Why Treating UTI in Pregnancy is Critical
Treating urinary tract infections during pregnancy is essential because untreated bacteriuria increases the risk of pyelonephritis from 20-35% to as high as 30%, and is associated with preterm delivery, low birth weight, and serious maternal complications including sepsis. 1, 2, 1
The Evidence for Treatment
Maternal Morbidity: Pyelonephritis Prevention
The most compelling reason to treat UTIs in pregnancy is preventing progression to pyelonephritis. Multiple randomized controlled trials from the 1960s-1980s consistently demonstrated that:
- Untreated asymptomatic bacteriuria (ASB) leads to pyelonephritis in 20-35% of cases
- Treatment reduces this risk to 1-4% 1, 2, 1
This represents a dramatic 85-95% relative risk reduction. Even a recent 2015 Dutch study that questioned universal screening still found a 2.4% pyelonephritis rate in untreated ASB—higher than in treated or uninfected women 1. The 2019 IDSA guidelines maintain a strong recommendation for screening and treating ASB in pregnancy based on moderate-quality evidence 1.
Neonatal Outcomes: Preterm Birth and Low Birth Weight
Treatment of bacteriuria reduces adverse neonatal outcomes:
- Preterm birth risk decreases from 53 per 1000 to 14 per 1000 (risk difference: -39 per 1000) 1
- Very low birth weight decreases from 137 per 1000 to 88 per 1000 (risk difference: -49 per 1000) 1
These effects are clinically significant and justify treatment even when considering antimicrobial stewardship concerns 1, 2, 1.
Clinical Algorithm for Management
Screening Approach
- Obtain urine culture at initial prenatal visit (12-16 weeks gestation optimal) 1
- Do not use urinalysis or pyuria alone—sensitivity is only 50% for detecting bacteriuria 2
- ASB is defined as ≥100,000 organisms/mL in asymptomatic women 2
Treatment Duration
Treat for 4-7 days rather than single-dose therapy (weak recommendation, low-quality evidence) 1:
- Single-dose regimens show lower clearance rates
- Seven-day nitrofurantoin was more effective than single-dose in preventing low birth weight (RR 1.65,95% CI 1.06-2.57) 1
- β-lactams and nitrofurantoin require longer courses than fluoroquinolones (which are contraindicated in pregnancy)
Preferred Antimicrobials
Use pregnancy-safe agents 1:
- Nitrofurantoin (avoid near term due to hemolysis risk)
- β-lactams (ampicillin, cephalexin)
- Fosfomycin (limited data but appears safe)
Avoid:
- Fluoroquinolones (teratogenic)
- Sulfonamides near term (kernicterus risk)
- Tetracyclines (bone/teeth effects)
Important Caveats and Pitfalls
The Dutch Study Controversy
A 2015 Netherlands study suggested selective screening might suffice for low-risk women, showing only 2.4% pyelonephritis in untreated ASB 1. However:
- The study was underpowered for its nested RCT
- Used only single urine culture (less reliable)
- Enrolled low-risk women only (not generalizable)
- Netherlands has excellent healthcare access for rapid treatment if symptoms develop
The IDSA panel concluded this approach requires further validation before changing universal screening recommendations 1.
When Screening May Be Insufficient
A single negative culture at 12-16 weeks still leaves a 1-2% risk of developing pyelonephritis later in pregnancy 2. However, evidence is insufficient to recommend routine repeat screening in women with initially negative cultures 1.
Risk Factor-Based Approach (Emerging)
Recent literature suggests selective screening for high-risk women with 3:
- Previous UTI
- Diabetes mellitus
- Urinary tract abnormalities
- Immunosuppression
- History of preterm birth
This approach balances antimicrobial stewardship with clinical benefit but is not yet endorsed by major guidelines and should not replace universal screening in standard practice 3.
The Bottom Line
The benefits of treating UTIs in pregnancy—preventing pyelonephritis (85-95% reduction), preterm birth, and low birth weight—far outweigh the risks of short-course antimicrobial therapy. The evidence is consistent across decades of research, and serious antimicrobial adverse effects occur much less frequently than the complications prevented 1. Universal screening with urine culture and treatment of positive results remains the standard of care 1.